Stock Track | 3SBIO Soars 5.30% Intraday on Clinical Trial Approval and Institutional Endorsement

Stock Track

Apr 17

3SBIO's stock price soared 5.30% during intraday trading on Friday, reflecting significant investor interest in the biopharmaceutical company.

The rally was primarily driven by the recent clinical trial approval of the company's key pipeline asset SSGJ-707, a bispecific antibody developed in collaboration with Pfizer. The drug has been approved for two significant clinical indications: first-line treatment of transformed small cell lung cancer in combination with chemotherapy, and monotherapy or combination therapy for locally advanced or metastatic renal cell carcinoma.

Additionally, institutional endorsement provided further support for the stock movement, with Morgan Stanley maintaining its "Overweight" rating on 3SBIO with a target price of HK$34, implying approximately 29% upside potential from current levels.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1129574663"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129574663\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129574663?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 09:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129574663","market":"hk","top_or_hot":-1,"title":"Stock Track | 3SBIO Soars 5.30% Intraday on Clinical Trial Approval and Institutional Endorsement","media":"Stock Track","content":"<p>3SBIO's stock price soared 5.30% during intraday trading on Friday, reflecting significant investor interest in the biopharmaceutical company.</p><p>The rally was primarily driven by the recent clinical trial approval of the company's key pipeline asset SSGJ-707, a bispecific antibody developed in collaboration with Pfizer. The drug has been approved for two significant clinical indications: first-line treatment of transformed small cell lung cancer in combination with chemotherapy, and monotherapy or combination therapy for locally advanced or metastatic renal cell carcinoma.</p><p>Additionally, institutional endorsement provided further support for the stock movement, with Morgan Stanley maintaining its \"Overweight\" rating on 3SBIO with a target price of HK$34, implying approximately 29% upside potential from current levels.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 3SBIO Soars 5.30% Intraday on Clinical Trial Approval and Institutional Endorsement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 3SBIO Soars 5.30% Intraday on Clinical Trial Approval and Institutional Endorsement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-17 09:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3SBIO's stock price soared 5.30% during intraday trading on Friday, reflecting significant investor interest in the biopharmaceutical company.</p><p>The rally was primarily driven by the recent clinical trial approval of the company's key pipeline asset SSGJ-707, a bispecific antibody developed in collaboration with Pfizer. The drug has been approved for two significant clinical indications: first-line treatment of transformed small cell lung cancer in combination with chemotherapy, and monotherapy or combination therapy for locally advanced or metastatic renal cell carcinoma.</p><p>Additionally, institutional endorsement provided further support for the stock movement, with Morgan Stanley maintaining its \"Overweight\" rating on 3SBIO with a target price of HK$34, implying approximately 29% upside potential from current levels.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1129574663","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129574663","pubTimestamp":1776389864,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"3SBIO's stock price soared 5.30% during intraday trading on Friday, reflecting significant investor interest in the biopharmaceutical company.The rally was primarily driven by the recent clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"个股赛道|三生制药盘中大涨5.30%获临床试验批文及机构背书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBIO's stock price soared 5.30% during intraday trading on Friday, reflecting significant investor interest in the biopharmaceutical company.The rally was primarily driven by the recent clinical trial approval of the company's key pipeline asset SSGJ-707, a bispecific antibody developed in collaboration with Pfizer. The drug has been approved for two significant clinical indications: first-line treatment of transformed small cell lung cancer in combination with chemotherapy, and monotherapy or combination therapy for locally advanced or metastatic renal cell carcinoma.Additionally, institutional endorsement provided further support for the stock movement, with Morgan Stanley maintaining its \"Overweight\" rating on 3SBIO with a target price of HK$34, implying approximately 29% upside potential from current levels.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}